Gilead Sciences Company Insiders
| GILD Stock | USD 90.49 0.30 0.33% |
About 85 percent of Gilead Sciences' insiders are selling. The analysis of the overall insider sentiment regarding Gilead Sciences suggests that quite a large number of insiders are terrified. Gilead Sciences employs about 18 K people. The company is managed by 13 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 1384.62 employees per reported executive.
| Daniel ODay Chairman Chairman of the Board, CEO |
| Jyoti Mehra President Executive Vice President of Human Resources |
Gilead Sciences' Insider Buying Vs Selling
15
Selling | Buying |
Latest Trades
| 2024-11-06 | Merdad Parsey | Disposed 25590 @ 91.5 | View | ||
| 2024-10-01 | Merdad Parsey | Disposed 2000 @ 83.83 | View | ||
| 2024-09-12 | Johanna Mercier | Disposed 29357 @ 83.78 | View | ||
| 2024-08-13 | Johanna Mercier | Disposed 5490 @ 73.98 | View | ||
| 2024-07-01 | Merdad Parsey | Disposed 2000 @ 68.63 | View | ||
| 2024-05-10 | Tommy Tuberville | Acquired @ 65.96 | |||
| 2024-05-08 | Tommy Tuberville | Disposed @ 64.92 | |||
| 2024-04-05 | Tommy Tuberville | Acquired @ 69.58 | |||
| 2024-04-03 | Tommy Tuberville | Disposed @ 70.89 | |||
| 2024-04-01 | Merdad Parsey | Disposed 2000 @ 72.96 | View | ||
| 2024-02-28 | Merdad Parsey | Disposed 2000 @ 73.18 | View | ||
| 2024-01-16 | Andrew D Dickinson | Disposed 5000 @ 85.78 | View | ||
| 2024-01-09 | Johanna Mercier | Disposed 8242 @ 85.23 | View |
Monitoring Gilead Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Gilead Sciences' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Gilead Sciences. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Gilead Sciences' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Gilead |
Gilead Sciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Gilead Sciences' future performance. Based on our forecasts, it is anticipated that Gilead will maintain a workforce of about 18000 employees by December 2024.Gilead Sciences' latest congressional trading
Congressional trading in companies like Gilead Sciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Gilead Sciences by those in governmental positions are based on the same information available to the general public.
| 2024-06-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-06-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-05-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2020-09-29 | Representative Ed Perlmutter | Acquired Under $15K | Verify | ||
| 2019-11-13 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
| 2018-10-18 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2018-10-17 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2018-08-10 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2018-08-09 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2018-05-22 | Senator Angus King | Acquired Under $15K | Verify | ||
| 2017-10-12 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify | ||
| 2017-10-11 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2017-04-11 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
| 2017-04-10 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
| 2017-01-05 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
| 2016-08-22 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2016-08-21 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2016-02-03 | Senator James Inhofe | Acquired $15K to $50K | Verify | ||
| 2015-07-09 | Senator James Inhofe | Acquired $50K to $100K | Verify |
Gilead Sciences Management Team Effectiveness
The company has return on total asset (ROA) of 0.1196 % which means that it generated a profit of $0.1196 on every $100 spent on assets. This is way below average. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. At present, Gilead Sciences' Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.26, whereas Return On Capital Employed is forecasted to decline to 0.08. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.The current year's Common Stock Shares Outstanding is expected to grow to about 1.5 B, whereas Net Income Applicable To Common Shares is forecasted to decline to about 4.9 B.
Gilead Sciences Workforce Comparison
Gilead Sciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 551,600. Gilead Sciences holds roughly 18,000 in number of employees claiming about 3% of equities under Health Care industry.
Gilead Sciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Gilead Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.2857 | 2 | 7 | 25,514 | 58,346 |
| 2024-09-01 | 0.4167 | 10 | 24 | 60,471 | 142,504 |
| 2024-06-01 | 1.4375 | 23 | 16 | 143,223 | 36,440 |
| 2024-03-01 | 1.3333 | 36 | 27 | 1,266,642 | 267,582 |
| 2023-12-01 | 0.5333 | 8 | 15 | 18,447 | 31,737 |
| 2023-09-01 | 0.5263 | 10 | 19 | 38,304 | 60,680 |
| 2023-06-01 | 1.6923 | 22 | 13 | 112,501 | 38,058 |
| 2023-03-01 | 1.25 | 40 | 32 | 1,128,676 | 266,434 |
| 2022-12-01 | 0.4762 | 10 | 21 | 36,382 | 88,490 |
| 2022-09-01 | 0.5 | 8 | 16 | 16,694 | 80,872 |
| 2022-06-01 | 1.625 | 39 | 24 | 299,224 | 63,903 |
| 2022-03-01 | 1.2571 | 44 | 35 | 1,633,427 | 229,097 |
| 2021-12-01 | 0.8333 | 5 | 6 | 9,450 | 12,612 |
| 2021-09-01 | 1.1429 | 8 | 7 | 23,658 | 41,537 |
| 2021-06-01 | 2.4 | 24 | 10 | 168,644 | 74,893 |
| 2021-03-01 | 1.2727 | 42 | 33 | 1,402,589 | 189,827 |
| 2020-12-01 | 1.1818 | 13 | 11 | 53,390 | 49,439 |
| 2020-09-01 | 0.8571 | 6 | 7 | 13,446 | 19,331 |
| 2020-06-01 | 1.28 | 32 | 25 | 131,108 | 91,601 |
| 2020-03-01 | 0.8571 | 48 | 56 | 947,653 | 442,930 |
| 2019-12-01 | 0.48 | 12 | 25 | 211,478 | 343,962 |
| 2019-09-01 | 1.0 | 7 | 7 | 191,617 | 26,356 |
| 2019-06-01 | 1.3913 | 32 | 23 | 178,370 | 97,544 |
| 2019-03-01 | 2.7692 | 36 | 13 | 929,034 | 83,253 |
| 2018-12-01 | 0.625 | 10 | 16 | 558,351 | 725,117 |
| 2018-09-01 | 0.75 | 9 | 12 | 155,008 | 304,469 |
| 2018-06-01 | 0.7083 | 34 | 48 | 457,671 | 1,147,635 |
| 2018-03-01 | 0.9298 | 53 | 57 | 1,234,973 | 909,350 |
| 2017-12-01 | 0.5172 | 15 | 29 | 492,516 | 994,620 |
| 2017-09-01 | 0.6471 | 22 | 34 | 425,338 | 1,019,734 |
| 2017-06-01 | 1.5882 | 27 | 17 | 339,440 | 487,336 |
| 2017-03-01 | 1.5385 | 40 | 26 | 1,350,400 | 687,274 |
| 2016-12-01 | 0.3214 | 9 | 28 | 435,518 | 1,405,006 |
| 2016-09-01 | 0.5806 | 18 | 31 | 1,298,480 | 2,019,883 |
| 2016-06-01 | 0.875 | 42 | 48 | 896,658 | 1,544,093 |
| 2016-03-01 | 1.2424 | 41 | 33 | 1,551,153 | 1,165,038 |
| 2015-12-01 | 0.3625 | 29 | 80 | 1,055,327 | 2,145,346 |
| 2015-09-01 | 0.4167 | 30 | 72 | 1,263,033 | 2,600,238 |
| 2015-06-01 | 0.6897 | 60 | 87 | 1,071,786 | 2,039,036 |
| 2015-03-01 | 0.6944 | 50 | 72 | 2,155,801 | 2,132,415 |
| 2014-12-01 | 0.3488 | 30 | 86 | 1,099,268 | 2,489,076 |
| 2014-09-01 | 0.4118 | 28 | 68 | 850,943 | 1,710,788 |
| 2014-06-01 | 0.7742 | 48 | 62 | 776,261 | 1,389,602 |
| 2014-03-01 | 0.6269 | 42 | 67 | 1,189,150 | 1,990,741 |
| 2013-12-01 | 0.32 | 8 | 25 | 523,826 | 1,389,573 |
| 2013-09-01 | 0.65 | 26 | 40 | 888,373 | 1,771,840 |
| 2013-06-01 | 1.4091 | 31 | 22 | 2,552,914 | 2,599,503 |
| 2013-03-01 | 0.6875 | 11 | 16 | 327,177 | 462,178 |
| 2012-12-01 | 0.575 | 23 | 40 | 744,171 | 1,268,288 |
| 2012-09-01 | 0.6667 | 22 | 33 | 491,253 | 568,788 |
| 2012-06-01 | 2.6667 | 32 | 12 | 142,089 | 44,794 |
| 2012-03-01 | 0.9091 | 20 | 22 | 514,883 | 374,311 |
| 2011-12-01 | 0.8333 | 5 | 6 | 201,000 | 15,566 |
| 2011-09-01 | 1.0 | 7 | 7 | 26,671 | 22,736 |
| 2011-06-01 | 2.3077 | 30 | 13 | 164,938 | 47,570 |
| 2011-03-01 | 1.1667 | 14 | 12 | 587,746 | 62,706 |
| 2010-12-01 | 0.4545 | 5 | 11 | 126,000 | 246,747 |
| 2010-09-01 | 3.5 | 7 | 2 | 173,873 | 154,000 |
| 2010-06-01 | 8.0 | 32 | 4 | 191,503 | 15,100 |
| 2010-03-01 | 1.0 | 18 | 18 | 419,444 | 307,236 |
| 2009-12-01 | 0.5625 | 9 | 16 | 185,000 | 355,520 |
| 2009-09-01 | 0.9091 | 20 | 22 | 501,469 | 907,765 |
| 2009-06-01 | 1.3158 | 25 | 19 | 442,080 | 626,500 |
| 2009-03-01 | 0.7917 | 19 | 24 | 630,200 | 697,742 |
| 2008-12-01 | 0.5556 | 15 | 27 | 536,850 | 831,037 |
| 2008-09-01 | 0.375 | 15 | 40 | 667,528 | 853,200 |
| 2008-06-01 | 0.156 | 22 | 141 | 702,213 | 759,587 |
| 2008-03-01 | 0.1391 | 21 | 151 | 881,400 | 732,627 |
| 2007-12-01 | 0.0412 | 7 | 170 | 343,000 | 718,550 |
| 2007-09-01 | 0.1765 | 9 | 51 | 420,000 | 476,000 |
| 2007-06-01 | 0.2 | 18 | 90 | 612,696 | 823,592 |
| 2007-03-01 | 0.1868 | 17 | 91 | 683,000 | 516,920 |
| 2006-12-01 | 0.0839 | 12 | 143 | 446,600 | 786,670 |
| 2006-09-01 | 0.0885 | 10 | 113 | 282,381 | 551,792 |
| 2006-06-01 | 0.4815 | 13 | 27 | 398,750 | 314,500 |
| 2006-03-01 | 0.2466 | 18 | 73 | 781,500 | 633,710 |
| 2005-12-01 | 0.1772 | 14 | 79 | 370,386 | 665,776 |
| 2005-09-01 | 0.5652 | 13 | 23 | 463,562 | 509,704 |
| 2005-06-01 | 0.1702 | 24 | 141 | 1,081,672 | 954,662 |
| 2005-03-01 | 0.6471 | 11 | 17 | 652,296 | 402,889 |
| 2004-12-01 | 0.4516 | 14 | 31 | 628,064 | 665,566 |
| 2004-09-01 | 0.4074 | 11 | 27 | 140,993 | 259,120 |
| 2004-06-01 | 1.5556 | 14 | 9 | 249,353 | 164,000 |
| 2004-03-01 | 0.8462 | 22 | 26 | 542,500 | 268,515 |
| 2003-12-01 | 0.3333 | 5 | 15 | 212,000 | 311,500 |
| 2003-09-01 | 0.3284 | 22 | 67 | 361,457 | 609,258 |
| 2003-06-01 | 1.0 | 2 | 2 | 716.00 | 33,880 |
Gilead Sciences Notable Stakeholders
A Gilead Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gilead Sciences often face trade-offs trying to please all of them. Gilead Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gilead Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel ODay | Chairman of the Board, CEO | Profile | |
| Jyoti Mehra | Executive Vice President of Human Resources | Profile | |
| Andrew Dickinson | Executive Vice President - Corporate Development and Strategy | Profile | |
| Sandra Patterson | Corporate VP | Profile | |
| Johanna Mercier | Chief Commercial Officer | Profile | |
| Michael Quigley | VP Biology | Profile | |
| Linda Higgins | Innovation Research | Profile | |
| Deborah Telman | General Affairs | Profile | |
| Deborah JD | General Affairs | Profile | |
| Jacquie CFA | Vice Relations | Profile | |
| Diane Wilfong | Corp VP | Profile | |
| Flavius MD | Executive Research | Profile | |
| Rudolf Ertl | Canada, Australia | Profile |
About Gilead Sciences Management Performance
The success or failure of an entity such as Gilead Sciences often depends on how effective the management is. Gilead Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gilead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gilead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.21 | 0.22 | |
| Return On Capital Employed | 0.15 | 0.08 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.25 | 0.26 |
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.
Gilead Sciences Workforce Analysis
Traditionally, organizations such as Gilead Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gilead Sciences within its industry.Gilead Sciences Manpower Efficiency
Return on Gilead Sciences Manpower
| Revenue Per Employee | 1.5M | |
| Revenue Per Executive | 2.1B | |
| Net Income Per Employee | 311.8K | |
| Net Income Per Executive | 431.8M | |
| Working Capital Per Employee | 266.9K | |
| Working Capital Per Executive | 369.6M |
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |